Provides practical guidelines for the clinical use of amiodarone in the management of supraventricular and ventricular arrhythmias.
Answers are grounded in this paper and cite their sources.
Amiodarone may improve outcomes in high-risk arrhythmia patients; leaves open its optimal place among therapies pending further RCTs.
Amiodarone has become an important drug for the treatment of supraventricular and ventricular arrhythmias, in short-term inpatient and outpatient settings. It may also have a role in affecting outcome in patients at high risk for arrhythmic events and sudden death; its place among available therapies is being established in clinical trials.
No takes yet. Share an insight, caveat, or question.
Nora Goldschlager (2000) studied this question. Amiodarone is an important treatment for supraventricular and ventricular arrhythmias, with an emerging role in improving outcomes for patients at high risk for arrhythmic events and sudden death.
Synapse has enriched 10 related papers. Consider them for comparative context: